Editorial: Ovarian cancer targeted medication: PARP inhibitors, anti-angiogenic drugs, immunotherapy, and more, volume II by Zhi-Bin Wang, Zhi-Bin Wang, Zhi-Bin Wang, De-Hua Liao, Guang Lei, Zhao-Qian Liu, Zhao-Qian Liu, Nayiyuan Wu, Nayiyuan Wu, Jing Wang, Jing Wang

Subjects: Get full text

Multi-stage structure-based virtual screening approach combining 3D pharmacophore, docking and molecular dynamic simulation towards the identification of potential selective PARP-1... by Mahmoud A. El Hassab, Wagdy M. Eldehna, Ghaneya S. Hassan, Sahar M. Abou-Seri

Subjects: Get full text

Poly-ADP ribose polymerase (PARP) inhibitor regimens for platinum-sensitive ovarian cancer in randomized, double-blind, phase III controlled trials: protocol for a systematic revie... by Xiaolian Peng, Jie Liu

Subjects: “…PARP inhibitor…”
Get full text

Efficacy of PARPi re-maintenance therapy for recurrent ovarian cancer by Yulin Wang, Yunjie Yang, Binghong Guo, Binghong Guo, Xiaoyan Li, Renakezi Tuersun, Ye Cao, Jundong Li, Jihong Liu, Su Li, Tao Liu, Yongwen Huang

Subjects: Get full text

Simultaneously delivery of functional gallium ions and hydrogen sulfide to endow potentiated treatment efficacy in chemo- and PARPi-resistant ovarian cancer by Sangsang Tang, Yangyang Li, Yifeng Fang, Mengyan Tu, Shenglong Wu, Yixuan Cen, Junfen Xu

Subjects: Get full text

PARP‐1 Inhibition Increases Oxidative Stress in Ets‐1‐Expressing MDA‐MB‐231 Breast Cancer Cells by Magalie Hervieu, Arnaud J. Legrand, Emilie Floquet, Thierry Idziorek, Corentin Spriet, Didier Monté, Vincent Villeret, Marc Aumercier, Souhaila Choul‐li

Subjects: Get full text

Poly ADP-Ribosylation in a Plant Pathogenic Oomycete <i>Phytophthora infestans</i>: A Key Controller of Growth and Host Plant Colonisation by Viktoriya O. Samarskaya, Sofya Koblova, Tatiana Suprunova, Eugene A. Rogozhin, Nadezhda Spechenkova, Sofiya Yakunina, Andrew J. Love, Natalia O. Kalinina, Michael Taliansky

Subjects: Get full text

CDK4/6 inhibitors promote PARP1 degradation and synergize with PARP inhibitors in non-small cell lung cancer by Carlos M Roggero, Anwesha B Ghosh, Anvita Devineni, Shihong Ma, Eliot Blatt, Ganesh V. Raj, Yi Yin

Subjects: Get full text

Tousled-like kinase loss confers PARP inhibitor resistance in BRCA1-mutated cancers by impeding non-homologous end joining repair by Min-ah Kim, Banseok Kim, Jihyeon Jeon, Jonghyun Lee, Hyeji Jang, Minjae Baek, Sang-Uk Seo, Dongkwan Shin, Anindya Dutta, Kyung Yong Lee

Subjects: Get full text

PARP inhibitor‐based treatment in metastatic, castration‐resistant prostate cancer (mCRPC): A systematic review and meta‐analysis by Michela Roberto, Mattia Alberto Di Civita, Daniele Marinelli, Andrea Torchia, Nertila Cara, Giulia Maltese, Iolanda Speranza, Daniele Santini

Subjects: “…poly‐ADP ribose polymerase (PARP) inhibitors…”
Get full text